Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
复制标题
DOI：
10.1182/blood.v94.7.2208.419k21_2208_2216
复制
发表时间：
1999-10
期刊：
影响因子：
20.3
通讯作者：
R. Curtis;L. Travis;P. Rowlings;G. Socié;D. Kingma;P. Banks;E. Jaffe;G. Sale;M. Horowitz
中科院分区：
文献类型：
--
作者：
R. Curtis;L. Travis;P. Rowlings;G. Socié;D. Kingma;P. Banks;E. Jaffe;G. Sale;M. Horowitz
我们评估了全球235个中心的18,014名接受异基因骨髓移植(BMT)的患者，以检查移植后淋巴增生性疾病(PTLD)的发生率和危险因素。78例受者发生PTLD，其中发生于移植后不到1年。10年PTLD累积发病率为1.0%+/-0.3%。移植后1至5个月的发病率最高(120例/10,000例/年)，随后在一年内存活的患者中急剧下降至不到5/10,000/年。在多因素分析中，早发PTLD(/=3个主要危险因素)的危险性分别为8.0%+/-2.9%和22%+/-17.9%。我们的结论是，与免疫改变和T细胞调节机制相关的因素都是早发性和晚发性PTLD的预测因子。
We evaluated 18,014 patients who underwent allogeneic bone marrow transplantation (BMT) at 235 centers worldwide to examine the incidence of and risk factors for posttransplant lymphoproliferative disorders (PTLD). PTLD developed in 78 recipients, with 64 cases occurring less than 1 year after transplantation. The cumulative incidence of PTLD was 1.0% +/- 0.3% at 10 years. Incidence was highest 1 to 5 months posttransplant (120 cases/10,000 patients/yr) followed by a steep decline to less than 5/10,000/yr among >/=1-year survivors. In multivariate analyses, risk of early-onset PTLD (/=3 major risk factors were 8.0% +/- 2.9% and 22% +/- 17.9%, respectively. We conclude that factors associated with altered immunity and T-cell regulatory mechanisms are predictors of both early- and late-onset PTLD.